FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Feb 20, 2020 at 11:52 PM.

  1. #1 cafead, Feb 20, 2020 at 11:52 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,028
    Likes Received:
    3
    via The Food and Drug Administration (FDA) has given BioMarin Pharmaceutical (NASDAQ: BMRN) a priority review for its valoctocogene roxaparvovec (valrox) gene therapy to treat patients with hemophilia A. The priority review will shave four months off of the review time for the marketing application, compared to a standard review. The agency expects to make a decision by Aug. 21, 2020.

    article source
     
    Quote

Reply to Thread